Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention

Kismet K., Akay M., Abbasoglu O., Ercan A.

CANCER DETECTION AND PREVENTION, cilt.28, sa.2, ss.127-142, 2004 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 28 Konu: 2
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1016/j.cdp.2003.12.005
  • Sayfa Sayıları: ss.127-142


Non-steroidal anti-inflaminatory drugs (NSAIDs) are the most widely used therapeutic agents in the treatment of pain, inflammation and fever. They may also have a role in the management of cancer prevention, Alzheimer's disease and prophylaxis against cardiovascular disease. These drugs act primarily by inhibiting cyclooxygenase enzyme, which has two isoforms, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Selective COX-2 inhibitors provide potent anti-inflammatory and analgesic effects without the side effects of gastric and renal toxicity and inhibition of platelet function. Celecoxib is a potent COX-2 inhibitor being developed for the treatment of rheumatoid arthritis and osteoarthritis. Chemoprevention is the use of pharmacological or natural agents to prevent, suppress, interrupt or reverse the process of carcinogenesis. For this purpose, celecoxib is being used for different cancer types. The effects of NSAIDs on tumor growth remain unclear, but are most likely to be multifocal. In this article, we reviewed COX-2 selectivity, the pharmacological properties of celecoxib, the use of celecoxib for cancer prevention and the mechanisms of chemoprevention. (C) 2004 Published by Elsevier Ltd. on behalf of International Society for Preventive Oncology.